DOVA News and Press, Dova Pharmaceuticals Inc. From 10/11/19

NEW YORK , Oct. 11, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City , is investigating: Dova Pharmaceuticals, Inc  ( DOV...

Shares of drugmaker Dova Pharmaceuticals (NASDAQ: DOVA) rose by 86.5% in September, according to data provided by S&P Global Market Intelligence . This added to Dova's big gains in 2019, piggybacking on a June jump of 59.9%. Year to date, the company's shares have skyrocketed 271.2%. A...

Merger activity increased last week with five new deals announced and five deals closing. Deal Statistics: New Deals: The acquisition of Dova Pharmaceuticals (DOVA) by Swedish Orphan Biovitrum AB (BIOVF) for $915 million. Under the terms of the agreement, Dova stockholders will ...

Monday was a solid day on Wall Street, as market participants seemed to be more optimistic that contentious issues affecting stocks will reach resolutions. In particular, a calming of tensions between the U.S. and China seemed to ease investors' nerves, especially after fears that Washington mig...

DOVA stock climbed Monday after Dova Pharmaceuticals (NASDAQ:DOVA) announced a buyout offer from a Swedish drugmaker, Orphan Biovitrum. Here’s everything we know about the deal, from start to finish. DOVA Stock Goes Flying on Buyout News On September 30, Dova Pharmaceuticals&#x...

Gainers:  Dova Pharmaceuticals (NASDAQ: DOVA ) +38% . USA Technologies ( OTC:USAT ) +28% . Farmmi (NASDAQ: FAMI ) +24% . Thor Industries (NYSE: THO ) +21% . GTT Communications (NYSE: GTT ) +15% . Patrick Industries (NASDAQ: PATK ) +12% . Seattle Genetics (NASDAQ: SGEN ) +10% . ...

Dova Pharmaceuticals (NASDAQ: DOVA ) is up  38%  premarket after entering into an agreement and plan of merger with Swedish Orphan Biovitrum AB ( OTCPK:BIOVF ) (Sobi). More news on: Dova Pharmaceuticals, Inc., Swedish Orphan Biovitrum AB (publ), Healthcare stocks news, Stocks o...

Dova Pharmaceuticals (NASDAQ: DOVA ) +39%  on being acquired by Sobi. More news on: Dova Pharmaceuticals, Inc., Bed Bath & Beyond Inc., ImmunoGen, Inc., Stocks on the move, Read more ...

Consideration of up to $29.00 per share includes $27.50 per share in upfront cash and an additional $1.50 per share upon regulatory approval of DOPTELET ® for chemotherapy-induced thrombocytopenia (CIT) as a Contingent Value Right (CVR) for a total potential consideration of up to $...

DURHAM, N.C., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Jason Hoitt, Chief Commercial Officer, will present a company overview at the 2019 Cantor Global Healthcare Conference on Wednesday, October 2, 2019 at 4:10 p.m. ET in New York, N...